ASH 2020 | ZUMA-5: axi-cel for R/R iNHL
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the primary analysis of the ZUMA-5 trial (NCT03105336), a Phase II, multicenter, single-arm study of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Prof. Neelapu discusses the high efficacy of axi-cel among all iNHL subgroups, however higher overall and complete response rates were observed, particularly among patients with follicular lymphoma (FL). Various secondary efficacy endpoints were assessed, including complete response (CR) rate, duration of response (DOR) and progression-free survival (PFS). Axi-cel was well tolerated, where the most common grade 3 and above adverse events were cytokine release syndrome (CRS) and neural toxicity. No grade 5 neurological events were recorded. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
SSN served as Advisory Board member or consultant for Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, and Unum Therapeutics; received research support from Kite, a Gilead Company, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, and Acerta; received royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy.
